TheraVasc, based in Shreveport, Louisiana, wants to raise $2.5 million in a Series A round, said President Tony Giordano. It would close on most of the money by the fall and launch a Phase Ib clinical trial to test how its drug, TV1001i, works to restore blood vessels damaged through peripheral artery disease.